Filing Flows › Health Care › Interpace Biosciences (IDXG)
Interpace Biosciences (IDXG) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 10, 2026 · Interpace Biosciences (IDXG) Q2 2026 earnings results →
Q2 2026 Revenue down 1% year over year to $9.1M · 2¢ of every $1 of revenue kept as net profit · operating margin 3.5%
Interpace Biosciences made $9.1M in Q2 2026 (-1% Y/Y). Operating margin 3.5%, net earnings $158K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 10, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.1M in Q2 2026, down 1% year over year and up 1% from the previous quarter.
Gross margin was 61.9%, up 4.8 points from Q2 2025. Operating profit was $321K, a 3.5% margin (up 8.6 points year over year). Operating expenses fell 7% while revenue fell 1%. The fastest-growing cost line was General & admin (+12%). Net earnings were $158K. The effective tax rate was 28.8%.
Operating cash flow was $98K (down 81% year over year), 62% of net earnings. Non-cash charges added back $127K of depreciation and amortization and $4K of share-based compensation. Working capital and other items used $191K. Capital expenditures of $57K left free cash flow of $41K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 10, 2026 | $9.1M | -1% | 3.5% | $158K | $98K |
| Q1 2026 | 10-Q | May 12, 2026 | $9.0M | -22% | 12.4% | $721K | $283K |
| Q4 2025 | 10-K | Mar 30, 2026 | $9.2M | -26% | 17.1% | $22.7M | $2.1M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $8.8M | -29% | 13.1% | $911K | $1.9M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $9.2M | -23% | -5.1% | −$640K | $520K |
| Q1 2025 | 10-Q | May 8, 2025 | $11.5M | +13% | 15.9% | $1.6M | $1.2M |
| Q4 2024 | 10-K | Mar 31, 2025 | $12.4M | +22% | 16.6% | $1.9M | $1.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 27% of its revenue · Stated in 10-K (sentence) · source
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has two commercialized molecular tests: ThyGeNEXT ® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and ThyraMIR ® v2, used in combination with ThyGeNEXT ® , for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.
In its own words, from its 8-K, filed Aug 12, 2026.
Interpace Biosciences against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -1% against the peers' median +5%. Operating margin: 3.5% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IDXG Interpace Biosciences | Q2 2026 | $9.1M | -1% | 3.5% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Interpace Biosciences 10-Q on SEC EDGAR · CIK 1054102 · Surgical & Medical Instruments & Apparatus
More on IDXG
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results